All of DSpace

Browsing by Subject "rivaroxaban"

Now showing items 1-20 of 45

    • Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation 

      Tiili P., Leventis I., Kinnunen J., Svedjebäck I., Lehto M., Karagkiozi E., Sagris D., Ntaios G., Putaala J. (2021)
      Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have superior safety and comparable efficacy profile compared to vitamin-K antagonists (VKAs), with more convenient dosing schemes. However, issues with ...

    • Analysis of the quality of reporting of randomized controlled trials in anticoagulant versus antiplatelet medication for venous thromboembolism prophylaxis as governed by the CONSORT statement 

      Beneki E., Vrysis C., Zintzaras E., Doxani C. (2021)
      Randomized controlled trials (RCTs) are the gold standard research in evaluating healthcare interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement improves the quality of RCTs in an evidence-based ...

    • Antimicrobial activity of bee-collected pollen and beebread: State of the art and future perspectives 

      Didaras N.A., Karatasou K., Dimitriou T.G., Amoutzias G.D., Mossialos D. (2020)
      Bee-collected pollen (BCP) is a well-known functional food. Honey bees process the collected pollen and store it in the hive, inside the comb cells. The processed pollen is called beebread or ambrosia and it is the main ...

    • Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial 

      Ntaios G., Pearce L.A., Meseguer E., Endres M., Amarenco P., Ozturk S., Lang W., Bornstein N.M., Molina C.A., Pagola J., Mundl H., Berkowitz S.D., Liu Y.Y., Sen S., Connolly S.J., Hart R.G. (2019)
      Background and Purpose- Aortic arch atherosclerosis (AAA) is a possible source of embolism in patients with embolic stroke of undetermined source. Previous studies reported high rates of embolic events in patients with ...

    • Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer 

      Pagkopoulou E., Simopoulou T., Maragkouli E., Perifanou-Sotiri S., Kotsakis A., Bogdanos D.P. (2020)
      Immune checkpoint inhibitors (ICIs) are a new class of drug that have demonstrated efficacy across many cancer types. Because of their nature and mode of action, ICIs unleash immune activation raising concerns as to whether ...

    • Assessment of the reporting quality of RCTs for novel oral anticoagulants in venous thromboembolic disease based on the CONSORT statement 

      Liampas I., Chlinos A., Siokas V., Brotis A., Dardiotis E. (2019)
      Randomized controlled trials (RCTs) are the cornerstone of evidence based medicine. Ιt is crucial that RCTs have transparent reporting to facilitate their interpretation. The purpose of the present study is the evaluation ...

    • Atrial cardiopathy and nonstenosing large artery plaque in patients with embolic stroke of undetermined source 

      Kamel H., Pearce L.A., Ntaios G., Gladstone D.J., Perera K., Roine R.O., Meseguer E., Shoamanesh A., Berkowitz S.D., Mundl H., Sharma M., Connolly S.J., Hart R.G., Healey J.S. (2020)
      Background and Purpose—Atrial cardiopathy and atherosclerotic plaque are two potential mechanisms underlying embolic strokes of undetermined source (ESUS). The relationship between these two mechanisms among ESUS patients ...

    • Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression 

      Sagris D., Leventis I., Georgiopoulos G., Korompoki E., Makaritsis K., Vemmos K., Milionis H., Lip G.Y.H., Ntaios G. (2020)
      Background: A considerable proportion of patients with atrial fibrillation (AF) are still treated with aspirin despite current guidelines due to presumed favorable safety. Aim: We performed a systematic review and meta-analysis ...

    • Causes and Risk Factors of Cerebral Ischemic Events in Patients with Atrial Fibrillation Treated with Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention: The RENo Study 

      Paciaroni M., Agnelli G., Caso V., Silvestrelli G., Seiffge D.J., Engelter S., De Marchis G.M., Polymeris A., Zedde M.L., Yaghi S., Michel P., Eskandari A., Antonenko K., Sohn S.-I., Cappellari M., Tassinari T., Tassi R., Masotti L., Katsanos A.H., Giannopoulos S., Acciarresi M., Alberti A., Venti M., Mosconi M.G., Vedovati M.C., Pierini P., Giustozzi M., Lotti E.M., Ntaios G., Kargiotis O., Monaco S., Lochner P., Bandini F., Liantinioti C., Palaiodimou L., Abdul-Rahim A.H., Lees K., Mancuso M., Pantoni L., Rosa S., Bertora P., Galliazzo S., Ageno W., Toso E., Angelini F., Chiti A., Orlandi G., Denti L., Flomin Y., Marcheselli S., Mumoli N., Rimoldi A., Verrengia E., Schirinzi E., Del Sette M., Papamichalis P., Komnos A., Popovic N., Zarkov M., Rocco A., Diomedi M., Giorli E., Ciccone A., Grory B.C.M., Furie K.L., Bonetti B., Saia V., Guideri F., Acampa M., Martini G., Grifoni E., Padroni M., Karagkiozi E., Perlepe K., Makaritsis K., Mannino M., MacCarrone M., Ulivi L., Giannini N., Ferrari E., Pezzini A., Doronin B., Volodina V., Baldi A., D'Amore C., Deleu D., Corea F., Putaala J., Santalucia P., Nardi K., Risitano A., Toni D., Tsivgoulis G. (2019)
      Background and Purpose-Despite treatment with oral anticoagulants, patients with nonvalvular atrial fibrillation (AF) may experience ischemic cerebrovascular events. The aims of this case-control study in patients with AF ...

    • Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial 

      Kasner S.E., Lavados P., Sharma M., Wang Y., Wang Y., Dávalos A., Shamalov N., Cunha L., Lindgren A., Mikulik R., Arauz A., Lang W., Czlonkowska A., Eckstein J., Gagliardi R., Amarenco P., Ameriso S.F., Tatlisumak T., Veltkamp R., Hankey G.J., Toni D.S., Bereczki D., Uchiyama S., Ntaios G., Yoon B.-W., Brouns R., DeVries Basson M.M., Endres M., Muir K., Bornstein N., Ozturk S., O'Donnell M., Mundl H., Pater C., Weitz J., Peacock W.F., Swaminathan B., Kirsch B., Berkowitz S.D., Peters G., Pare G., Themeles E., Shoamanesh A., Connolly S.J., Hart R.G., NAVIGATE ESUS Steering Committee and Investigators (2018)
      Background: The New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs. ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE-ESUS) trial is a randomized phase-III trial comparing ...

    • Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece 

      Gourzoulidis G., Kourlaba G., Kakisis J., Matsagkas M., Giannakoulas G., Gourgoulianis K.I., Vassilakopoulos T., Maniadakis N. (2017)
      Background and Objective: Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a major healthcare concern that results in substantial morbidity and mortality with great economic ...

    • Direct oral anticoagulant-vs Vitamin K antagonist-related nontraumatic intracerebral hemorrhage 

      Tsivgoulis G., Lioutas V.-A., Varelas P., Katsanos A.H., Goyal N., Mikulik R., Barlinn K., Krogias C., Sharma V.K., Vadikolias K., Dardiotis E., Karapanayiotides T., Pappa A., Zompola C., Triantafyllou S., Kargiotis O., Ioakeimidis M., Giannopoulos S., Kerro A., Tsantes A., Mehta C., Jones M., Schroeder C., Norton C., Bonakis A., Chang J., Alexandrov A.W., Mitsias P., Alexandrov A.V. (2017)
      Objective: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular ...

    • Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study 

      Paciaroni M., Agnelli G., Falocci N., Tsivgoulis G., Vadikolias K., Liantinioti C., Chondrogianni M., Bovi P., Carletti M., Cappellari M., Zedde M., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Silvestrelli G., Lanari A., Ciccone A., Putaala J., Tomppo L., Tatlisumak T., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D'Amore C., Becattini C., Mosconi M.G., Cimini L.A., Soloperto R., Masotti L., Vannucchi V., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Sohn S.-I., Marcheselli S., Mumoli N., De Lodovici M.L., Bono G., Furie K.L., Tadi P., Yaghi S., Toni D., Letteri F., Tassinari T., Kargiotis O., Lotti E.M., Flomin Y., Mancuso M., Maccarrone M., Giannini N., Bandini F., Pezzini A., Poli L., Padovani A., Scoditti U., Denti L., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Gourbali V., Orlandi G., Giuntini M., Chiti A., Giorli E., Gialdini G., Corea F., Ageno W., Bellesini M., Colombo G., Monaco S., Baronello M.M., Karapanayiotides T., Caso V. (2017)
      Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated ...

    • Early recurrence in paroxysmal versus sustained atrial fibrillation in patients with acute ischaemic stroke 

      Paciaroni M., Angelini F., Agnelli G., Tsivgoulis G., Furie K.L., Tadi P., Becattini C., Falocci N., Zedde M., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., Altavilla R., D’Amore C., Mosconi M.G., Cimini L.A., Bovi P., Carletti M., Rigatelli A., Cappellari M., Putaala J., Tomppo L., Tatlisumak T., Bandini F., Marcheselli S., Pezzini A., Poli L., Padovani A., Masotti L., Vannucchi V., Sohn S.-I., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Vadikolias K., Liantinioti C., Chondrogianni M., Mumoli N., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Corea F., Ageno W., Bellesini M., Silvestrelli G., Ciccone A., Scoditti U., Denti L., Mancuso M., Maccarrone M., Orlandi G., Giannini N., Gialdini G., Tassinari T., Lodovici M.L.D., Bono G., Rueckert C., Baldi A., Toni D., Letteri F., Giuntini M., Lotti E.M., Flomin Y., Pieroni A., Kargiotis O., Karapanayiotides T., Monaco S., Baronello M.M., Csiba L., Szabó L., Chiti A., Giorli E., Sette M.D., Imberti D., Zabzuni D., Doronin B., Volodina V., Michel Pd-Mer P., Vanacker P., Barlinn K., Pallesen L.P., Kepplinger J., Deleu D., Melikyan G., Ibrahim F., Akhtar N., Gourbali V., Yaghi S., Caso V. (2019)
      Background: The relationship between different patterns of atrial fibrillation and early recurrence after an acute ischaemic stroke is unclear. Purpose: In a prospective cohort study, we evaluated the rates of early ischaemic ...

    • Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies 

      Archontakis-Barakakis P., Li W., Kalaitzoglou D., Tzelves L., Manolopoulos A., Giannopoulos S., Giamouzis G., Giannakoulas G., Batsidis A., Palaiodimos L., Ntaios G., Lip G.Y.H., Kokkinidis D.G. (2022)
      Aims: Observational studies have investigated the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial fibrillation. We performed a systematic review ...

    • Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis 

      Ntaios G., Swaminathan B., Berkowitz S.D., Gagliardi R.J., Lang W., Siegler J.E., Lavados P., Mundl H., Bornstein N., Meseguer E., Amarenco P., Cucchiara B., Camps-Renom P., Makaritsis K., Korompoki E., Papavasileiou V., Marti-Fabregas J., Milionis H., Vemmos K., Connolly S.J., Hart R.G. (2019)
      Background and Purpose - The sources of emboli in patients with embolic stroke of undetermined source (ESUS) are multiple and may not respond uniformly to anticoagulation. In this exploratory subgroup analysis of patients ...

    • Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: A systematic review and meta-analysis 

      Karathanos C., Nana P., Spanos K., Kouvelos G., Brotis A., Matsagas M., Giannoukas A. (2021)
      Objective: Direct oral anticoagulants (DOACs) have been recommended for the treatment of deep vein thrombosis (DVT). However, the benefits are uncertain for the prevention of post-thrombotic syndrome (PTS). We performed a ...

    • Embolic Stroke of Undetermined Source: JACC Review Topic of the Week 

      Ntaios G. (2020)
      The term embolic stroke of undetermined source (ESUS) was introduced in 2014 to describe patients with a nonlacunar ischemic stroke and no convincing etiology. The terms ESUS and cryptogenic stroke are not synonyms, as the ...

    • Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias 

      Bawazeer G.A., Alkofide H.A., Alsharafi A.A., Babakr N.O., Altorkistani A.M., Kashour T.S., Miligkos M., AlFaleh K.M., Al-Ansary L.A. (2021)
      Background: The management of anticoagulation therapy around the time of catheter ablation (CA) procedure for adults with arrhythmia is critical and yet is variable in clinical practice. The ideal approach for safe and ...

    • Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy 

      Ameriso S.F., Amarenco P., Pearce L.A., Perera K.S., Ntaios G., Lang W., Bereczki D., Uchiyama S., Kasner S.E., Yoon B.-W., Lavados P., Firstenfeld A., Mikulik R., Povedano G.P., Ferrari J., Mundl H., Berkowitz S.D., Connolly S.J., Hart R.G. (2020)
      Background: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of ...